Regeneron Reports Second Quarter 2016 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Vistra Energy (VST) Reports Q2 results
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Regeneron Pharma (REGN) PT Trimmed to $511 at Leerink Partners
August 5, 2016 8:03 AM EDTLeerink Partners analyst Geoffrey Porges trims its price target on Regeneron Pharma (NASDAQ: REGN) to $511.00 (from $530.00) but maintains an Outperform rating amid solid Q2 results.
Porges commented, "Regeneron announced solid 2Q16 results, with Eylea beating by 2% in the US and 5% overall; total... More
Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' Continues
August 4, 2016 2:55 PM EDTRoth Capital affirms Regeneron (Nasdaq: REGN) with a Buy rating and $520 price target following Q2 results and updated guidance, as reported... More
Regeneron (REGN) Tops Q2 EPS by 17c; Updates FY16 Expectations
August 4, 2016 6:32 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $2.82, $0.17 better than the analyst estimate of $2.65. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.24 billion.
Marketed Product Update
EYLEA® (aflibercept) Injection for Intravitreal Injection
In the second quarter of 2016, net sales of EYLEA in the United States increased 27% to $831 million from $655 million in the second quarter of 2015. Overall distributor inventory levels remained within the Company's one- to two-week targeted range.Bayer commercializes EYLEA outside the United States. In the... More